Recombinant coagulation factors. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Recombinant coagulation factors.

Blood Rev. 1997 Dec;11(4):169-77. Unique Identifier : AIDSLINE MED/98142446
Roddie PH; Ludlam CA; Department of Haematology, Royal Infirmary of Edinburgh, UK.

Abstract: The advent of technology that has allowed production of recombinant proteins on an industrial scale has revolutionized haemophilia care. Recombinant coagulation factors, as opposed to their plasma-derived counterparts, have a very low risk for transmission of infectious agents and their use should eradicate the threat of infection from viruses such as hepatitis C and the human immunodeficiency virus. This review outlines the manufacturing process involved in the production of the recombinant coagulation factors and the trials to date that have been performed to establish their safety and efficacy. We also discuss some of the issues involved in the change to use of recombinant coagulation factors, such as viral safety and potential immunogenicity.
Keywords: *Blood Coagulation Factors/BIOSYNTHESIS *Blood Coagulation Factors/GENETICS *Recombinant Proteins/BIOSYNTHESIS *Recombinant Proteins/GENETICSKWDbloodcoagulationfactors/biosynthesisKWDbloodcoagulationfactors/geneticsKWDrecombinantproteins/biosynthesisKWDrecombinantproteins/genetics
980630
M9861826

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .